Key result
The HNO donor Angeli's salt completely prevented Angiotensin II-induced cardiomyocyte hypertrophy and superoxide generation via cGMP-dependent mechanisms.
Why the study?
Does the HNO donor Angeli's salt prevent Angiotensin II-induced hypertrophy in neonatal rat cardiomyocytes?
Does the HNO donor Angeli's salt prevent Angiotensin II-induced hypertrophy in neonatal rat cardiomyocytes?
p-value: p=<0.001
The HNO donor Angeli's salt prevents cardiomyocyte hypertrophy and superoxide generation via cGMP-dependent signaling, highlighting HNO as a potential therapeutic target for cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Supports HNO donors as antihypertrophic targets; leaves open in vivo and clinical translation.
Lin et al. (2012) studied Cardiac hypertrophy. Angeli's salt (HNO donor) vs. Angiotensin II alone was evaluated on Cardiomyocyte 2D area (hypertrophy) (p=<0.001). The HNO donor Angeli's salt completely prevented Angiotensin II-induced cardiomyocyte hypertrophy and superoxide generation via cGMP-dependent mechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: